Bioventus (BVS) Short-term Investments (2021 - 2022)
Bioventus (BVS) reported Short-term Investments of $23000.0 for Q4 2022, down 99.56% on a YoY basis from $5.3 million in Q4 2021, and little changed quarter-over-quarter from $23000.0 in Q4 2022.
Bioventus (BVS) Short-term Investments (2021 - 2022) Analysis & Trends
Bioventus has reported Short-term Investments for 2 years, with the latest figure at $23000.0 in Q4 2022.
- For the quarter ending Q4 2022, Short-term Investments fell 99.56% year-over-year to $23000.0; the trailing twelve-month figure through Dec 2022 stood at $23000.0 (down 99.56% YoY), and the FY2022 full-year result was $23000.0, down 99.56% from the prior year.
- Short-term Investments for Q4 2022 stood at $23000.0, roughly flat from $23000.0 in the prior quarter.
- The five-year high for Short-term Investments was $5.3 million in Q4 2021, with the low at $23000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Bioventus | 571.68 Mn | 581.20 Mn | 90.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 23,000.00 |
| Oct 1, 2022 | 23,000.00 |
| Apr 2, 2022 | 5.28 Mn |
| Dec 31, 2021 | 5.28 Mn |
| Jul 3, 2021 | 2.00 Mn |
| Apr 3, 2021 | 5.21 Mn |